Abstract
Helicobacter pylori (H. pylori) is a Gram-negative spiral bacterium commonly found in the stomach. Major part of the world’s population is infected with H. pylori and is at increased risk of severe gastritis, peptic ulcer disease, and gastric cancer. Most studied virulence factors of the bacterium are the cytotoxin-associated gene (CagA) and the vacuolating cytotoxin A (VacA). The H. pylori infection is diagnosed by invasive (histological examination, culture, and rapid urease test, which require endoscopy and biopsy) and noninvasive methods (serology, urea breath test, and stool antigen test). H. pylori eradication is preferred for a long-term prevention of complications. Current treatments consist of antibiotics and adequate PPI dose and can be divided into two strands—with or without bismuth. Achieving an eradication rate of >90% is an indicator for effective treatment. Due to the increasing levels of antibiotic resistance, the standard triple therapy is largely replaced with a quadruple therapy, especially in countries with high resistance rates. Antimicrobial susceptibility testing should be performed after the second-line treatment failure, leading to an individualized patient treatment. Clear explanations and patients’ compliance are of great importance for a better outcome.
Keywords
- Helicobacter pylori
- virulence factors
- diagnostic methods
- treatment
1. Introduction
In the early 1980s,
Even though
This is why
2. H. pylori virulence factors
Vacuolating Cytotoxin (VacA) is also a major virulence factor present in almost all strains, and is highly polymorphic. VacA affects the cells with the induction of vacuole formation, mitochondrial dysfunction, modulation of signal transduction pathways, inhibition of T cell proliferation, and production of inflammatory cytokines. To favor its action, VacA binds to receptors such as receptor protein tyrosine phosphatases (RPTPα and RPTPβ), low-density lipoprotein receptor-related protein-1 (LRP1), fibronectin, CD18, and sphingomyelin. RPTPβ promote to ulceration and LRP1 is involved in the induction of autophagy. There is an interaction between cagA and VacA molecules, which is associated with the pathogenesis of gastric diseases. Therefore, further research on VacA may increase the knowledge of its role in the development of gastric disorders in
Duodenal ulcer-promoting gene A, dupA, is present in the tfs4 gene cluster and also the presence of the iceA1 allele of iceA is associated with increased risk for duodenal ulcer disease.
3. Helicobacter pylori -associated diseases
3.1 Dyspepsia
According to Rome III, functional dyspepsia (FD) is a symptomatic dyspepsia in the absence of structural or biochemical explanation after appropriate investigation [8]. There are gastrointestinal symptoms that are associated with chronic dyspepsia as epigastric pain, epigastric burning, uncomfortable postprandial fullness, and early satiation.
FD is one of the most common gastrointestinal diseases which affects the quality of life. Chronic dyspepsia symptoms, which are thought to be caused by
The evidence of the association between
3.2 Gastritis
Neutrophils, macrophages, and NK cells contribute to gastritis via the secretion of inflammatory and tissue-damaging factors including reactive oxygen and nitrogen species (ROS and RNS) [20], perforin, and granzymes [21]. However, DCs are semi-mature and tolerogenic in
It has recently been shown that retinoic acid (RA) is produced by human gastric epithelial cells and DCs regulates the level of inflammation. More intense inflammation and mucosal damage have been observed during
All of the above makes it clear that the hosts’ immune response is one of the major factors involved in the
3.3 Peptic ulcer disease
Around 95% of duodenal ulcers and around 70% of gastric ulcers are
On the other hand, in patients with corpus-predominant atrophy or pan-gastritis, the acid output can be normal or reduced, explained by the loss of parietal cells. A state of hypochlorhydria is established, despite increased gastrin production from the
In those with reduced numbers of Tregs in their gastric mucosa, peptic ulceration is more frequently found thus impaired capacity to control the inflammation [19, 29]. The inflammation and damage are enhanced by gastric Th1 and Th17 cells inducing epithelial cells to express higher levels of MHC class II and activation of mitogen-activated protein (MAP) kinases and transcription factors AP-1 and NF-jB [30].
3.4 Gastric adenocarcinoma
There are approximately 100,000 new cases of gastric cancer each year [31]. A majority of cases are registered in developing countries, half of them occurring in Eastern Asia. It is the fifth most common malignancy worldwide and the third most common cause of cancer-related death diagnosed usually at a late stage [32].
Depending on the location the gastric cancer can be divided into two subtypes:
Cardia—arising from epithelial cells at the gastroesophageal junction.
Non-cardia—arising from the distal stomach.
Cardia gastric cancers are thought to be mostly unrelated to
The gastric cancer is classified histologically as two types [34]:
intestinal—usually exophytic, often ulcerating, and are associated with intestinal metaplasia of the stomach and are more common in proximal (fundus) location.
diffuse-type—poorly differentiated infiltrating lesions, which lead to the thickening of the stomach (linitis plastica) and predominate in younger patients.
Patients with intestinal-type tumors appear to have a better prognosis than those with diffuse-type.
Chronic gastritis caused by
Genetically determined high expression of pro-inflammatory cytokines (IL-6, IL-8, TNFa, IL-1b), low expression of anti-inflammatory cytokines (IL-10, TGFb), or enhanced responsiveness to bacterial components (Toll-like receptors 1, 2, 4, 5, and 9) are associated with a higher risk of gastric adenocarcinoma [37, 38]. In the future, identification of molecular profiles for gastric cancer subtypes will lead to more personalized clinical management, therapeutic targets and biomarkers for screening, prognosis, prediction of response to treatment, and monitoring of gastric cancer progression [39].
3.5 MALT lymphoma
Almost all patients with gastric MALT lymphoma have an active
4. Diagnosis
Diagnosis of
From the noninvasive methods, 13C-UBT is the best approach to the diagnosis of
In clinical practice, when there is an indication for endoscopy, and there is no contraindication for biopsy, the rapid urease test (RUT) is recommended as a first-line diagnostic test [6]. The sensitivity of biopsy urease tests is approximately 90%, and specificity is in the range of 95–100% [52]. It has been shown that the best biopsy sites for detection of
Most cases of
The value of culture is primarily to perform AST for clarithromycin, levofloxacin, metronidazole, rifamycin, and eventually, amoxicillin and tetracycline. Several studies, using tailored treatments based on
A panel of serological tests (GastroPanel), including serum Pg (PgI and PgII), gastrin 17 (G-17), and anti-
In the post-treatment evaluation, UBT is a valid and reliable test in the assessment of
5. Treatment
Eradication rates of
All non-BQTs will be less effective in regions with dual resistance to clarithromycin and metronidazole >15% [73]. Non-bismuth quadruple concomitant therapy, prescribed for 14 days, can be an effective alternative in regions with high clarithromycin resistance (15–40%) but low to intermediate metronidazole resistance (<40%) [74]. Bismuth-containing quadruple therapies are the treatment of choice when we have high (>15%) dual clarithromycin and metronidazole resistance. Ideally, clarithromycin should be avoided and a combination of alternative antibiotics. If bismuth is not available in high dual clarithromycin and metronidazole resistance areas, levofloxacin [75], rifabutin [76], and high dose dual (PPI + amoxicillin) [77] treatments can be considered. Quadruple therapy with a PPI, bismuth, and a combination of two antibiotics, among furazolidone, tetracycline, metronidazole, and amoxicillin, has been successfully tested (>90% cure rates) against
Sequential therapy is more complex and requires switching of antibiotic drugs during the treatment course, which can confuse the patients. Concomitant therapy (PPI, amoxicillin, clarithromycin, and a nitroimidazole administered concurrently) is easier and similar to standard triple therapy and should be the preferred non-bismuth quadruple therapy. Sequential therapy achieves lower cure rates compared to concomitant therapy against clarithromycin-resistant strains [85, 86]. All non-BQTs (concomitant, hybrid, triple, and sequential) lead to excellent cure rates against susceptible
Response to PPI is individual and determined by cytochrome 2C19 and MDR polymorphisms. Caucasian subjects show a higher prevalence of high metabolizers (56–81%) compared to Asian [74]. Esomeprazole and rabeprazole provide better overall
For second-line treatment, after failure of PPI-clarithromycin-amoxicillin triple therapy, a bismuth-containing quadruple therapy or a fluoroquinolone-containing triple or quadruple therapy are recommended [94]. In theory, any treatment could be used after failure of BQT, including repeating the same BQT with longer duration and high metronidazole dosage. However, treatment that has already failed seems wiser never to be repeated. Bismuth therapies are usually proposed as first-line treatments for areas of high clarithromycin resistance and using a clarithromycin-containing treatment as second-line therapy after failure of a BQT does not seem to be practical. That is why Levofloxacin-based triple therapy, that is known to be effective as second-line therapy after clarithromycin-containing therapy, should also be recommended after failure of a bismuth-containing quadruple regimen [95, 96]. The incidence of side effects are lower with levofloxacin-containing triple therapy than with bismuth-containing quadruple therapy [97]. A sub-group analysis showed similar eradication rates with 500 and 1000 mg) of levofloxacin [97]. However, the efficacy of levofloxacin-based regimens may be affected by an increased prevalence of levofloxacin resistance [98]. Therefore, 14-day bismuth quadruple therapy is a valid second-line treatment for
After failure of the first-line treatment (clarithromycin based) and second-line treatment (with bismuth-containing quadruple regimen), it is recommended to use the fluoroquinolone-containing regimen as a rescue therapy. After failure of the first-line treatment (triple or non-bismuth quadruple) and second-line treatment (fluoroquinolone-containing therapy), it is recommended to use the bismuth-based quadruple therapy. Furthermore, BQT is not influenced by clarithromycin and fluoroquinolone resistance [102]. However, if a second-line treatment fails, culture with susceptibility testing (AST) or molecular determination of genotype resistance is recommended. Susceptibility-guided triple therapies proved more effective than empirical triple therapies in first-line treatment [55, 103].
6. Helicobacter pylori and extragastric diseases
Chronic infection with
The reflux of gastric contents and the failure of the esophagus to clear by peristaltic contractions lead to GERD. The severity of the disease depends strongly on the pH of the refluxed gastric juice [104, 105]. Chronic GERDs most likely to cause BE—replacement of the stratified squamous epithelium with a metaplastic columnar epithelium. The inflammation caused by chronic acid exposure appear to promote the development of EA from BE [106]. Patients subjected to endoscopy for any indications have the prevalence of BE, which is approximately 1–2% up to 5–15% in patients with GERD symptoms. Patients with BE have a 30- to 125-fold higher risk for developing EA, in comparison with the general population [107].
In 2013, Rubenstein et al. found an inverse correlation of
In 2012, Fischbach et al. documented a decreased risk of EA predominantly in patients infected with CagA-positive
Numerous studies have addressed whether
Inflammatory bowel diseases (IBDs) are chronic relapsing disorders of increasing incidence and two main forms—Crohn’s disease and ulcerative colitis. Intestinal inflammation and epithelial injury are characterized for the diseases. In Crohn’s disease, inflammation is discontinuous and can affect any part of the gastrointestinal tract and all layers of the bowel wall. In contrast, ulcerative colitis expands continuously from the rectum and affect the superficial layer of the mucosa. Modern hygienic practices and diet have been proposed to account for the increasing incidence of IBD in Western societies associated with changes in the human microbiota composition [113]. A correlation between
7. H. pylori and the human microbiota
8. Conclusion
References
- 1.
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1 (8390):1311-1315 - 2.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015; 65 (2):87-108. DOI: 10.3322/caac.21262 - 3.
Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori -induced gastric cancer. Gastroenterology. 2016;150 (1):64-78. DOI: 10.1053/j.gastro.2015.09.004 - 4.
Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: Ancient history, modern implications. The Journal of Clinical Investigation. 2009;119 (9):2475-2487. DOI: 10.1172/JCI38605 - 5.
Breckan RK, Paulssen EJ, Asfeldt AM, Kvamme JM, Straume B, Florholmen J. The all-age prevalence of Helicobacter pylori infection and potential transmission routes. A population-based study. Helicobacter. 2016;21 (6):586-595. DOI: 10.1111/hel.12316 - 6.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection—The Maastricht V/Florence Consensus Report. Gut. 2017;66 (1):6-30. DOI: 10.1136/gutjnl-2016-312288 - 7.
Suzuki H, Warren R, Marshall B. Helicobacter pylori . Japan: Springer; 2016. DOI: 10.1007/978-4-431-55705-0. ISBN: 978-4-431-55704-3 - 8.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al., European Helicobacter and Microbiota Study Group and Consensus Panel. Functional gastroduodenal disorders. Gastroenterology. 2006; 130 (5):1466-1479. DOI: 10.1053/j.gastro.2005.11.059 - 9.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64 (9):1353-1367. DOI: 10.1136/ gutjnl-2015-309252 - 10.
Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T, et al. Evidence-based clinical practice guidelines for functional dyspepsia. Journal of Gastroenterology. 2015; 50 (2):125-139. DOI: 10.1007/ s00535-014-1022-3 - 11.
Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: A meta-analysis. Gut. Jul 2015; 64 (7):1049-1057. DOI: 10.1136/gutjnl-2014-307843 - 12.
Zhao B, Zhao J, Cheng WF, Shi WJ, Liu W, Pan XL, et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: A meta-analysis of randomized controlled studies with 12-month follow-up. Journal of Clinical Gastroenterology. 2014;48 (3):241-247. DOI: 10.1097/MCG. 0b013e31829f2e25 - 13.
Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science. 1998;279 (5349):373-377 - 14.
Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science. 2002;297 (5581):573-578. DOI: 10.1126/science.1069076 - 15.
Rossez Y, Gosset P, Boneca IG, Magalhaes A, Ecobichon C, Reis CA, et al. The lacdiNAc-specific adhesin LabA mediates adhesion of Helicobacter pylori to human gastric mucosa. The Journal of Infectious Diseases. 2014;210 (8):1286-1295. DOI: 10.1093/infdis/jiu239 - 16.
Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nature Immunology. 2004;5 (11):1166-1174 - 17.
Kim DJ, Park JH, Franchi L, Backert S, Núñez G. The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1b production in Helicobacter pylori infected dendritic cells. European Journal of Immunology. 2013;43 (10):2650-2658. DOI: 10.1002/eji.201243281 - 18.
Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: Recent advances and novel insights. Trends in Cell Biology. 2015; 25 (5):308-315. DOI: 10.1016/j.tcb.2014.12.009 - 19.
Cook KW, Letley DP, Ingram RJ, Staples E, Skjoldmose H, Atherton JC, et al. CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori -infected human gastric mucosa. Gut. 2014;63 (10):1550-1559. DOI: 10.1136/gutjnl-2013-306253 - 20.
Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation. Frontiers in Immunology. 2014; 5 :514. DOI: 10.3389/fimmu.2014.00514 - 21.
Yun CH, Lundgren A, Azem J, Sjoling A, Holmgren J, Svennerholm AM, et al. Natural killer cells and Helicobacter pylori infection: Bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production. Infection and Immunity. 2005;73 (3):1482-1490 - 22.
Rizzuti D, Ang M, Sokollik C, Wu T, Abdullah M, Greenfield L, et al. Helicobacter pylori inhibits dendritic cell maturation via interleukin-10-mediated activation of the signal transducer and activator of transcription 3 pathway. Journal of Innate Immunity. 2015;7 (2):199-211. DOI: 10.1159/000368232 - 23.
Bimczok D, Kao JY, Zhang M, Cochrun S, Mannon P, Peter S, et al. Human gastric epithelial cells contribute to gastric immune regulation by providing retinoic acid to dendritic cells. Mucosal Immunology. May 2015; 8 (3):533-544. DOI: 10.1038/mi.2014.86 - 24.
Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: Cause or bystander. World Journal of Gastroenterology. 2014;20 (3):613-629. DOI: 10.3748/wjg.v20.i3.613 - 25.
Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori -specific immune tolerance, and asthma protection. The Journal of Clinical Investigation. 2012;122 (3):1082-1096. DOI: 10.1172/JCI61029 - 26.
Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori -positive people. Cochrane Database of Systematic Reviews. 2016;4 :CD003840. DOI: 10.1002/14651858.CD003840.pub5 - 27.
Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Digestive Diseases. 2011;29 (5):459-464. DOI: 10.1159/000332213 - 28.
Robinson K, Kenefeck R, Pidgeon EL, Shakib S, Patel S, Polson RJ, et al. Helicobacter pylori -induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut. 2008;57 (10):1375-1385 - 29.
Zhou Y, Toh ML, Zrioual S, Miossec P. IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine. 2007; 38 (3):157-164. DOI: 10.1016/j.cyto.2007.06.002 - 30.
Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015; 64 (12):1881-1888. DOI: 10.1136/gutjnl-2014-308915 - 31.
Herrero R, Park JY, Forman D. The fight against gastric cancer—The IARC Working Group report. Best Practice & Research. Clinical Gastroenterology. 2014; 28 (6):1107-1114. DOI: 10.1016/j.bpg.2014.10.003 - 32.
Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori . International Journal of Cancer. 2015;136 (2):487-490. DOI: 10.1002/ijc.28999 - 33.
Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica. 1965; 64 :31-49 - 34.
Malfertheiner P, Fry LC, Monkemuller K. Can gastric cancer be prevented by Helicobacter pylori eradication? Best Practice & Research. Clinical Gastroenterology. 2006;20 (4):709-719. DOI: 10.1016/j.bpg.2006.04.005 - 35.
Na HK, Woo JH. Helicobacter pylori induces hypermethylation of CpG islands through upregulation of DNA methyltransferase: Possible involvement of reactive oxygen/nitrogen species. Journal of Cancer Prevention. 2014;19 (4):259-264. DOI: 10.15430/JCP.2014.19.4.259 - 36.
Ramis IB, Vianna JS, Goncalves CV, von Groll A, Dellagostin OA, da Silva PE. Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori . Journal of Microbiology, Immunology, and Infection. 2015;9 (12):1535-1547. DOI: 10.1016/j.jmii.2015.03.002 - 37.
El-Omar EM, Ng MT, Hold GL. Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008; 27 (2):244-252 - 38.
Tegtmeyer N, Backert S. Molecular Pathogenesis and Signal Transduction by Helicobacter pylori . Part of Current Topics in Microbiology and Immunology. Cham, Switzerland: Springer International Publishing AG; 2017;400 . DOI: 10.1007/978-3-319-50520-6. ISBN: 978-3-319-50519-0 - 39.
Genta RM, Hamner HW, Graham DY. Gastric lymphoid follicles in Helicobacter pylori infection: Frequency, distribution, and response to triple therapy. Human Pathology. 1993;24 (6):577-583 - 40.
Du MQ , Atherton JC. Molecular subtyping of gastric MALT lymphomas: Implications for prognosis and management. Gut. 2006; 55 (6):886-893 - 41.
Fischbach W. Gastric MALT lymphoma—Update on diagnosis and treatment. Best Practice & Research. Clinical Gastroenterology. 2014; 28 (6):1069-1077. DOI: 10.1016/j.bpg.2014.09.006 - 42.
Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: Biological and therapeutic relevance. Blood. 2016; 127 (17):2082-2092. DOI: 10.1182/blood-2015-12-624304 - 43.
Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. The American Journal of Gastroenterology. 2004;99 :823-829 - 44.
Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori . European Journal of Gastroenterology & Hepatology. 1999;11 :1135-1138 - 45.
Savarino V, Tracci D, Dulbecco P, et al. Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori . The American Journal of Gastroenterology. 2001;96 :348-352 - 46.
Dulbecco P, Gambaro C, Bilardi C, et al. Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. Digestive Diseases and Sciences. 2003; 48 :315-321 - 47.
Gisbert JP, Calvet X. Helicobacter pylori ‘test-and-treat’ strategy for management of dyspepsia: A comprehensive review. Clinical and Translational Gastroenterology. 2013;4 :e32 - 48.
Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection—A critical review. Alimentary Pharmacology & Therapeutics. 2004;20 :1001-1017 - 49.
Nocon M, Kuhlmann A, Leodolter A, et al. Efficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technology Assessment. 2009;5 :Doc14 - 50.
Ferwana M, Abdulmajeed I, Alhajiahmed A, et al. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis. World Journal of Gastroenterology. 2015;21 :1305-1314 - 51.
Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis. The American Journal of Gastroenterology. 2006;101 :1921-1930 - 52.
El-Zimaity HM, Al-Assi MT, Genta RM, et al. Confirmation of successful therapy of Helicobacter pylori infection: Number and site of biopsies or a rapid urease test. The American Journal of Gastroenterology. 1995;90 :1962-1964 - 53.
Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. The American Journal of Gastroenterology. 1998;93 :569-573 - 54.
Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. The American Journal of Surgical Pathology. 1996; 20 :1161-1181 - 55.
Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Internal Medicine. 2010;49 :1103-1109 - 56.
Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World Journal of Gastroenterology. 2014;20 :6400-6411 - 57.
Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa. Endoscopy. 2012; 44 :74-94 - 58.
Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Advances in Medical Sciences. 2011; 56 :145-150 - 59.
McNicholl AG, Forné M, Barrio J, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. European Journal of Gastroenterology & Hepatology. 2014; 26 :941-948 - 60.
Leodolter A, Domínguez-Muñoz JE, von Arnim U, et al. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. The American Journal of Gastroenterology. 1999;94 :2100-2104 - 61.
Vaira D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Annals of Internal Medicine. 2002;136 :280-287 - 62.
Chey WD, Metz DC, Shaw S, et al. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. The American Journal of Gastroenterology. 2000;95 :1171-1174 - 63.
Neil GA, Suchower LJ, Ronca PD, et al. Time of Helicobacter pylori eradication assessment following treatment. Helicobacter. 1997;2 :13-20 - 64.
Chey WD, Leontiadis GI, Howde CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology. 2017;112 :212-238. DOI: 10.1038/ajg.2016.563 - 65.
Thung I, Aramin H, Vavinskaya V, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Alimentary Pharmacology & Therapeutics. 2016;43 :514-533 - 66.
Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. Journal of Clinical Microbiology. 2007;45 :4006-4010 - 67.
Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18 :206-214 - 68.
Khademi F, Poursina F, Hosseini E, et al. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iranian Journal of Basic Medical Sciences. 2015;18 :2-7 - 69.
Karamanolis GP, Daikos GL, Xouris D, et al. The evolution of Helicobacter pylori antibiotic resistance over 10 years in Greece. Digestion. 2014;90 :229-231 - 70.
Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62 :34-42 - 71.
Boyanova L, Gergova G, Evstatiev I, et al. Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infectious Diseases (London). 2016;48 :56-62 - 72.
Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: A multicenter, prospective, randomized controlled study in Japan. Journal of Clinical Gastroenterology. 2015;49 :468-471 - 73.
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. Clinical Gastroenterology and Hepatology. 2014;12 :177-186 - 74.
Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World Journal of Gastroenterology. 2014;20 :10338-10347 - 75.
Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology. 2012;143 :55.e1-61.e1; quiz e13-14 - 76.
Toracchio S, Capodicasa S, Soraja DB, et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Digestive and Liver Disease. 2005;37 :33-38 - 77.
Ince AT, Tozlu M, Baysal B, et al. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepato-Gastroenterology. 2014;61 :1454-1458 - 78.
Liang X, Xu X, Zheng Q , et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clinical Gastroenterology and Hepatology. 2013;11 :802.e1-807. e1 - 79.
Liu WZ, Xie Y, Cheng H, et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. Journal of Digestive Diseases. 2013;14 :211-221 - 80.
Fischbach L, Evans EL. Meta-analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori . Alimentary Pharmacology & Therapeutics. 2007;26 :343-357 - 81.
Graham DY, Shiotani A. Which therapy for Helicobacter pylori infection? Gastroenterology. 2012;143 :10-12 - 82.
Salazar CO, Cardenas VM, Reddy RK, et al. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: A pilot study in US Hispanics. Helicobacter. 2012;17 :382-390 - 83.
Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nature Reviews. Gastroenterology & Hepatology. 2011;8 :79-88 - 84.
Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori : Lessons from China. European Journal of Gastroenterology & Hepatology. 2013;25 :1134-1140 - 85.
Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori : A multicentre, open-label, randomised trial. Lancet. 2013;381 :205-213 - 86.
Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ. 2013;347 :f4587 - 87.
Tang HL, Li Y, Hu YF, et al. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. PLoS One. 2013;8 :e62162 - 88.
Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. The American Journal of Gastroenterology. 2006;101 :1467-1475 - 89.
Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis. Helicobacter. 2008;13 :532-541 - 90.
McNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: Esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2012;36 :414-425 - 91.
Tokoro C, Inamori M, Koide T, et al. Does pretreatment with proton pump inhibitors influence the eradication rate of Helicobacter pylori ? Hepato-Gastroenterology. 2010;57 :1645-1649 - 92.
Yoon SB, Park JM, Lee JY, et al. Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates. World Journal of Gastroenterology. 2014;20 :1061-1066 - 93.
Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Practice & Research. Clinical Gastroenterology. 2001;15 :413-431 - 94.
Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opinion on Pharmacotherapy. 2013;14 :843-861 - 95.
Gisbert JP, Morena F. Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary Pharmacology & Therapeutics. 2006;23 :35-44 - 96.
Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-analysis. The American Journal of Gastroenterology. 2006;101 :488-496 - 97.
Di Caro S, Fini L, Daoud Y, et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World Journal of Gastroenterology. 2012;18 :5669-5678 - 98.
Saracino IM, Zullo A, Holton J, et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. Journal of Gastrointestinal and Liver Diseases. 2012;21 :363-365 - 99.
Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Alimentary Pharmacology & Therapeutics. 2015;41 :768-775 - 100.
Malfertheiner P. Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication. Nature Reviews. Gastroenterology & Hepatology. 2010;7 :538-539 - 101.
Liao J, Zheng Q , Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013; 18 :373-377 - 102.
Malfertheiner P, Link A, Selgrad M. Helicobacter pylori : Perspectives and time trends. Nature Reviews. Gastroenterology & Hepatology. 2014;11 :628-638 - 103.
López-Góngora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: Susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. The Journal of Antimicrobial Chemotherapy. 2015;70 :2447-2455 - 104.
Collen MJ, Johnson DA, Sheridan MJ. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy. Digestive Diseases and Sciences. 1994; 39 (2):410-417 - 105.
Gardner JD, Sloan S, Robinson M, Miner PB Jr. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor. Alimentary Pharmacology & Therapeutics. 2004; 20 (11-12):1381-1386. DOI: 10.1111/j.1365-2036.2004.02279.x - 106.
Lao-Sirieix P, Corovic A, Jankowski J, Lowe A, Triadafilopoulos G, Fitzgerald RC. Physiological and molecular analysis of acid loading mechanisms in squamous and Helicobacter pylori and extragastric diseases 343 columnar-lined esophagus. Diseases of the Esophagus. 2008;21 (6):529-538. DOI: 10.1111/j.1442-2050.2007.00807.x - 107.
Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology Clinics of North America. 2015; 44 (2):203-231. DOI: 10.1016/j.gtc.2015.02.001 - 108.
Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis,Helicobacter pylori and extragastric diseases 345 and gastroesophageal reflux symptoms. Clinical Gastroenterology and Hepatology. 2014;12 (2):239-245. DOI: 10.1016/j.cgh.2013.08.029 - 109.
Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012; 149 :1578-1593. DOI: 10.1016/j.cell.2012.04.037 - 110.
Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, et al. Background factors of reflux esophagitis and non-erosive reflux disease: A cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013; 8 (7):e69891. DOI: 10.1371/journal.pone.0069891 - 111.
Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, et al. The association between Barrett’s esophagus and Helicobacter pylori infection: A meta-analysis. Helicobacter. 2012;17 (3):163-175. DOI: 10.1111/j.1523-5378.2011.00931.x - 112.
Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: A meta-analysis. Diseases of the Esophagus. 2014;27 (7):645-653. DOI: 10.1111/dote.12194 - 113.
Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D’Haens G, et al. IBD around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010—Inflammatory bowel disease task force meeting. Inflammatory Bowel Diseases. 2011; 17 (2):639-644. DOI: 10.1002/ibd.21409 - 114.
Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology. 2000;12 (4):439-443 - 115.
Pronai L, Schandl L, Orosz Z, Magyar P, Tulassay Z. Lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease—Antibiotic use in the history does not play a significant role. Helicobacter. 2004;9 (3):278-283. DOI: 10.1111/j.1083-4389.2004.00223.xHEL223 - 116.
Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. Journal of Clinical Gastroenterology. 2003;36 (1):22-25 - 117.
Wu XW, Ji HZ, Yang MF, Wu L, Wang FY. Helicobacter pylori infection and inflammatory bowel disease in Asians: A meta-analysis. World Journal of Gastroenterology. 2015;21 (15):4750-4756. DOI: 10.3748/wjg.v21.i15.4750 - 118.
Rokkas T, Gisbert JP, Niv Y, O’Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterology Journal. 2015;3 (6):539-550. DOI: 10.1177/205064061558088910.1177_2050640615580889 - 119.
Castano-Rodriguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of Helicobacter andCampylobacter species in IBD: A systematic review and meta-analysis. Gut. Feb 2017;66 (2):235-249. DOI: 10.1136/gutjnl-2015-310545 - 120.
Andersson AF, Lindberg M, Jakobsson H, et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One. 2008; 3 :e2836 - 121.
Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103 :732-737 - 122.
Li XX, Wong GLH, To KF, et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One. 2009;4 :e7985 - 123.
Yang I, Nell S, Suerbaum S. Survival in hostile territory: The microbiota of the stomach. FEMS Microbiology Reviews. 2013; 37 :736-761 - 124.
Yang I, Woltemate S, Piazuelo MB, et al. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Scientific Reports. 2016; 6 :18594 - 125.
Debongnie JC, Donnay M, Mairesse J, et al. Gastric ulcers and Helicobacter heilmannii . European Journal of Gastroenterology & Hepatology. 1998;10 :251-254 - 126.
Matsumoto T, Kawakubo M, Akamatsu T, et al. Helicobacter heilmannii sensu stricto-related gastric ulcers: A case report. World Journal of Gastroenterology. 2014; 20 :3376-3382 - 127.
Morgner A, Bayerdörffer E, Meining A, et al. Helicobacter heilmannii and gastric cancer. Lancet. 1995;346 :511-512 - 128.
Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii -associated primary gastric low-grade MALT lymphoma: Complete remission after curing the infection. Gastroenterology. 2000;118 :821-828 - 129.
Haesebrouck F, Pasmans F, Flahou B, et al. Gastric Helicobacters in domestic animals and nonhuman primates and their significance for human health. Clinical Microbiology Reviews. 2009; 22 :202-223 - 130.
Stolte M, Kroher G, Meining A, et al. A comparison of Helicobacter pylori andH. heilmannii gastritis. A matched control study involving 404 patients. Scandinavian Journal of Gastroenterology. 1997;32 :28-33 - 131.
Ladirat SE, Schols HA, Nauta A, et al. High-throughput analysis of the impact of antibiotics on the human intestinal microbiota composition. Journal of Microbiological Methods. 2013; 92 :387-397 - 132.
Marteau P, Rambaud JC. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiology Reviews. 1993; 12 :207-220 - 133.
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. The New England Journal of Medicine. 2015;372 :825-834 - 134.
Dang Y, Reinhardt JD, Zhou X, et al. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: A meta-analysis. PLoS One. 2014;9 :e111030 - 135.
Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Experimental and Therapeutic Medicine. 2015;9 :707-716 - 136.
Tong JL, Ran ZH, Shen J, et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Alimentary Pharmacology & Therapeutics. 2007;25 :155-168 - 137.
Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. Journal of Clinical Gastroenterology. 2013;47 :25-32 - 138.
Zhang M-M, Qian W, Qin Y-Y, et al. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World Journal of Gastroenterology. 2015;21 :4345-4357 - 139.
Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: Evidence from a meta-analysis. Revista Española de Enfermedades Digestivas. 2013;105 :445-453 - 140.
Zhu R, Chen K, Zheng Y-Y, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World Journal of Gastroenterology. 2014;20 :18013-18021 - 141.
Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14 :97-107 - 142.
Vladimirov B. Treatment of helicobacter-pylori associated diseases. In: Boyanova L, editor. Helicobacter pylori. Norfolk, UK: Caister Academic Press; 2011:237-251 - 143.
Li S, Huang XL, Sui JZ, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. European Journal of Pediatrics. 2014;173 :153-161 - 144.
Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials. European Journal of Gastroenterology & Hepatology. 2009;21 :45-53 - 145.
Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication ofHelicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2015;41 :1237-1245